**Reliability of EP30S symptom criteria and nasal endoscopy
in the assessment of chronic rhinosinusitis - a GA²LEN study**

Journal:	<i>Allergy</i>
Manuscript ID:	ALL-2010-00660.R1
Wiley - Manuscript type:	Original Article: Epidemiology and Genetics
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Tomassen, Peter; Ghent University, Upper Airways Research Laboratory</p> <p>Newson, Roger; Imperial College, National Heart Lung Institute</p> <p>Hoffmans, Ruth; Academic Medical Center, Department of Otorhinolaryngology</p> <p>Lotvall, Jan; University of Gothenburg, Department of Internal Medicine</p> <p>Cardell, Lars Olaf; Department of Clinical Science, Intervention and Technology, Karolinska Institutet</p> <p>Gunnbjörnsdóttir, Maria; Akademiska Sjukhuset, Department of Medical Sciences: Respiratory Medicine and Allergology</p> <p>Thilsing, Trine; Odense University Hospital, Department of Occupational and Environmental Medicine</p> <p>Matricardi, Paolo; Charité University Medical Center, Paediatric Pneumology and Immunology</p> <p>Kramer, Ursula; Heinrich-Heine-University Düsseldorf, Institut für Umweltmedizinische Forschung</p> <p>Makowska, Joanna; Medical University of Lodz, Department of Immunology, Rheumatology and Allergy</p> <p>Brozek, Grzegorz; Medical University of Silesia, Department of Epidemiology</p> <p>Gjomarkaj, Mark; Consiglio Nazionale delle Ricerche, Istituto di Biomedicina e Immunologica Molecolare</p> <p>Howarth, Peter; Southampton University Hospital Trust, Infection, Inflammation and Immunology Division</p>
Keywords :	Questionnaires, Endoscopy, Validation Studies, Reproducibility of Results, Sinusitis and nasal polyps

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SCHOLARONE™
Manuscripts

For Peer Review

Reliability of EP3OS symptom criteria and nasal endoscopy in the assessment of chronic rhinosinusitis - a GA²LEN study.

Short title: Symptom and endoscopic criteria for CRS

Tomassen P¹, Newson RB², Hoffmans R³, Lotvall J⁴, Cardell L⁵, Gunnbjornsdottir M⁶, Thilsing T⁷, Matricardi P⁸, Kramer U⁹, Makowska JS¹⁰, Brozek G¹¹, Gjomarkaj M¹², Howarth P¹³, Loureiro C¹⁴, Toskala E¹⁵, Fokkens W³, Bachert C¹, Burney P², Jarvis D².

1. Upper Airway Research Laboratory,
Department of Otorhinolaryngology and Logopaedic-Audiologic Science,
Ghent University
Gent, Belgium
peter.tomassen@ugent.be

2. Respiratory Epidemiology and Public Health Group
National Heart and Lung Institute
Imperial College
London, UK
r.newson@imperial.ac.uk

3. Department of Otorhinolaryngology,
Academic Medical Centre
Amsterdam, the Netherlands
R.Hoffmans@amc.uva.nl

4. Krefting Research Centre
Department of Internal Medicine
University of Gothenburg
Göteborg, Sweden
jan.lotvall@mednet.gu.se

5. Department of Clinical Sciences, Intervention and Technology
Karolinska Institutet
S-141 86 Stockholm, Sweden
lars-olaf.cardell@ki.se

6. Department of Medical Sciences, Respiratory Medicine and Allergology
Akademiska Sjukhuset,
Uppsala, Sweden
maria.gunnbjornsdottir@medsci.uu.se

7. Dept. of Occupational and Environmental Medicine
Odense University Hospital
Odense, Denmark
trine.thilsing@ouh.regionsyddanmark.dk

8. Department of Pediatric Pneumology and Immunology,
Charité-Universitätsmedizin,
Berlin, Germany
paolo.matricardi@charite.de

9. Institut für Umweltmedizinische Forschung,
Heinrich-Heine-University Düsseldorf,
Düsseldorf, Germany.
kraemeru@uni-duesseldorf.de

10. Department of Immunology, Rheumatology and Allergy
Medical University of Lodz
Lodz, Poland

1
2
3 61 czajka@csk.umed.lodz.pl
4 62
5 63 11 Department of Epidemiology
6 64 Medical University of Silesia
7 65 18 Medyków Str.,
8 66 40-752 Katowice, PL
9 67 brozekg@mp.pl
10 68
11 69 12 Istituto di Biomedicina e Immunologia Molecolare
12 70 Consiglio Nazionale delle Ricerche
13 71 Palermo, Italy
14 72 gjomarkaj@ibim.cnr.it
15 73
16 74 13 Southampton University Hopital Trust
17 75 Tremona Road,
18 76 Southampton, United Kingdom.
19 77 phh1@soton.ac.uk
20 78
21 79 14. Hospitais da Universidade de Coimbra
22 80 Pulmonology Unit,
23 81 Hospitais da Universidade de Coimbra
24 82 Coimbra, Portugal
25 83 cl_loureiro@hotmail.com
26 84
27 85 15. Respiratory Diseases
28 86 Finnish Institute of Occupational Health
29 87 Helsinki, Finland
30 88 elina.toskala@ttl.fi
31 89
32 90
33 91 Corresponding author
34 92 Dr. Peter Tomassen
35 93 peter.tomassen@ugent.be
36 94
37 95 Study Support
38 96 All authors are members of Workpackage 1.2.1 of the Global Allergy and Asthma European Network and are
39 97 supported by the Sixth European Union Framework program for research, contract no. FOOD-CT-2004-506378
40 98
41 99 Keywords (MeSH)
42 100 Questionnaires
43 101 Endoscopy
44 102 Validation Studies
45 103 Reproducibility of Results
46 104 Sinusitis
47 105
48 106 Conflicts of interest
49 107 Jan Lötvall has received consultancy and speaker fees from AstraZeneca, GlaxoSmithKline, MSD/Merck,
50 108 Novartis, and Schering-Plough.
51 109
52 110 Author contributions
53 111 PT, RN, RH, and DJ analyzed the data and wrote the manuscript. WF, CB, PB and DJ conceived and supervised
54 112 the study. All authors collected data and critically revised the manuscript.
55 113
56 114 **Body word count: 2673**
57
58
59
60

ABSTRACT

Background: The European Position Paper on Rhinosinusitis and Nasal Polyps (EP3OS) incorporates symptomatic, endoscopic and radiologic criteria in the clinical diagnosis of chronic rhinosinusitis (CRS), while in epidemiological studies, the definition is based on symptoms only. We aimed to assess the reliability and validity of a symptom based definition of CRS using data from the GA2LEN European survey.

Methods: On two separate occasions, 1700 subjects from 11 centers provided information on symptoms of CRS, allergic rhinitis and asthma. CRS was defined by the epidemiological EP3OS symptom criteria. The difference in prevalence of CRS between two study points, the standardized absolute repeatability and the chance corrected repeatability (kappa) were determined. In two centers 342 participants underwent nasal endoscopy. The association of symptom-based CRS with endoscopy and self-reported doctor-diagnosed CRS was assessed.

Results: There was a decrease in prevalence of CRS between the two study phases, and this was consistent across all centers (-3.0%, 95% CI: -5.0 to -1.0%, $I^2 = 0$). There was fair to moderate agreement between the two occasions (kappa = 39.6). Symptom-based CRS was significantly associated with positive endoscopy in nonallergic subjects, and with self-reported doctor-diagnosed CRS in all subjects, irrespective of the presence of allergic rhinitis.

Conclusion: Our findings suggest that a symptom-based definition of CRS, according to the epidemiological part of the EP3OS criteria, has a moderate reliability over time, is stable between study centers, is not influenced by the presence of allergic rhinitis, and is suitable for the assessment of geographic variation in prevalence of CRS.

Abstract Word Count: 250

INTRODUCTION

Chronic rhinosinusitis (CRS), a disease defined as chronic inflammation of the nose and paranasal sinuses, has a considerable impact on morbidity and quality of life. There are varying estimates of disease prevalence based on a limited amount of data (1-4), and to date, no pan-European epidemiological study has been undertaken. The paucity of comparable and reliable data is in part related to the lack of uniformly accepted diagnostic criteria for CRS. Although a number of guidelines and consensus documents have been developed, considerable differences in diagnostic criteria and the lack of an accepted gold standard diagnosis make it difficult to make comparisons. Upper airway diseases present with a variable pattern of common symptoms such as nasal obstruction and discharge, making the epidemiological diagnosis of CRS difficult to differentiate from allergic and nonallergic rhinitis based on symptomatic grounds only. Moreover, not all patients presenting with symptoms meeting CRS criteria have evidence of disease if diagnosis is complemented with nasal endoscopy and CT. The 2007 EP3OS guideline (5) incorporates symptomatic, endoscopic and radiologic criteria in the clinical diagnosis of CRS. However, as nasal endoscopy and CT are difficult to apply in large-scale epidemiological studies, the EP3OS document defines CRS by symptoms only, when used in epidemiological studies. The repeatability and the validity of the EP3OS criteria have not yet been validated extensively. Recently, the Global Allergy and Asthma European Network of Excellence (GA²LEN) initiated a large epidemiological study comprising a postal survey (the GA²LEN Survey) followed by a case-control study (the GA²LEN Survey Follow-Up), on allergy, asthma and upper airway disease across Europe. In this study, diagnosis of CRS is based on a questionnaire for symptoms forming part of the EP3OS diagnostic criteria. The current study aims to validate this by reporting the repeatability of the epidemiological EP3OS symptom criteria, and by describing the relationship of symptom criteria and self-reported doctor-diagnosed CRS with findings from nasal endoscopy.

METHODS

Study design

In a first cross-sectional phase (the GA²LEN Survey), 11 participating centers sent a questionnaire by mail to a random sample of at least 3000 subjects aged 15 to 75 years, with up to three attempts to elicit a response. Samples were identified by random sampling from a population based local sampling frame. The questionnaire was newly developed for the diagnosis of chronic rhinosinusitis (Table 1). A positive diagnosis of chronic rhinosinusitis was based on symptoms as defined in the 2007 EP3OS epidemiological

criteria (Table 1); additionally, subjects were asked if a doctor had ever told whether the subject had CRS (further referred to as 'self-reported doctor-diagnosed CRS'). Asthma was defined as reporting 'having ever had asthma' and at least one of the following symptoms in the last 12 months: 1) wheeze or whistling in the chest; or 2) waking up with chest tightness, shortness of breath or an attack of coughing. Allergic rhinitis was defined by the self reported history of 'nasal allergy'.

In a second phase (the GA²LEN Survey Follow-Up), each center invited 120 randomly selected subjects with asthma, 120 with CRS, 40 with asthma and CRS and 120 with neither asthma or CRS for a clinical study visit with further investigations among which a questionnaire including the same questions as those described above for the postal survey.

Nasal endoscopy

In two centers (Ghent and Amsterdam), each participant in the Follow-Up phase was invited to undergo nasal endoscopy. Nasal endoscopy was performed, blinded to symptom status, by otorhinolaryngology specialists or residents using routine clinical rigid 30° endoscopes. An endoscopy positive for rhinosinusitis was defined, based on the EP3OS criteria, as presence of polyps, presence of oedema in the middle meatus or presence of thick purulent discharge in the middle meatus, at either nasal side.

Statistical methods

All data available to the coordinating center that had undergone full quality control by November 1st 2009 were included in this analysis. The prevalences of CRS, each of the symptoms of CRS, asthma and allergic rhinitis in the Survey and Follow-Up were estimated using data only from participants who had taken part in both. As the sample in the Follow-Up phase was selected based on disease in the Survey sample (and therefore had higher prevalences of asthma, CRS and both compared to the general population), prevalence estimates were standardized, for both CRS and asthma, to the original sampled population by using inverse sampling probability weights. The standardized difference in prevalence of disease between the two phases was estimated for each center and as an overall estimate (8). Variation of this difference between centers was estimated (Wald chi-square test for heterogeneity) and the I-squared heterogeneity measure was computed (9). Absolute repeatability (10), standardized to account for the high prevalence of asthma, CRS and both in the Follow-Up Phase, and Cohen's kappa (κ) statistics were derived, with confidence intervals calculated using the delta method with the normalizing transformation $\log(1 - \kappa)$.

The odds ratios of having CRS symptoms by endoscopy results or by self-reported doctor-diagnosed CRS were derived and tested with Pearson chi square test. To assess whether these associations were similar in subjects with and without current allergic rhinitis (defined as self-reported nasal allergy or hay fever, and sneezing, runny or blocked nose in the absence of a cold in the last 12 months), analyses were stratified by current allergic rhinitis, the Breslow-Day test was used to test for interaction, and the Mantel-Haenszel weighted odds ratio was calculated. Binomial confidence intervals according to Clopper and Pearson were calculated around proportions. All statistical analyses were carried out using Stata Version 11 (StataCorp, College Station, TX, USA) and SPSS Version 15 (SPSS Inc., Chicago, IL, USA).

RESULTS

Eleven centers in seven countries provided data from baseline and follow-up surveys to the coordinating center by November 2009. One center which had not yet completed the study was excluded. A total of 36790 subjects had completed the postal questionnaire, and 1700 subjects had been seen in the follow-up clinical visit. In this group, 652 were controls, 469 had asthma but no sinusitis, 411 had sinusitis but no asthma, 168 had asthma and sinusitis. Of these, 50.1% were female, the median age was 48.7 years (IQR 36.8 to 59.6 years), and the median time between postal survey and clinical visits was 287 days (IQR 205 to 359 days).

Results are based on the subjects who had taken part in both phases of the study (n = 1700). Table 2 shows the standardized difference in prevalence between the two study phases, the absolute repeatability (standardized for disease prevalence) and the unstandardized kappa statistic, for CRS, asthma, allergic rhinitis, and some of their related symptoms. Figure 1 illustrates the standardized difference in prevalence between the two study phases for the outcomes CRS, asthma and allergic rhinitis in each of the participating centers.

The prevalence of symptom-based CRS, estimated from the second phase, was lower than that obtained in the first phase (-3.0%; 95% CI -5.0 to -1.0%), and this difference was similar in all centers ($I^2 = 0$). Standardized absolute repeatability of symptom-based CRS was 91.8%, and the unstandardized kappa was 39.6. All of the individually reported symptoms that contributed to the symptom-based definition of CRS showed a pattern similar to that of CRS.

The prevalence of self-reported doctor-diagnosed CRS was lower than symptom-based CRS, with a marginally higher kappa (48.8). The standardized difference in prevalence showed an overall increase in prevalence in the second phase, with significant heterogeneity between centers ($I^2 = 52.0$; $p=0.028$). By comparison, the prevalence of wheezing with breathlessness showed a non-significant ($p=0.18$) fall between the two study phases

with significant variation between centers ($I^2 = 58.9$; $p=0.0095$). The unstandardized kappa (54.6) showed a moderate agreement. The prevalence of asthma showed no significant standardized difference between the baseline and clinical follow-up, with non-significant variation of this between centers ($I^2 = 41.5$; $p=0.082$). The reporting of a history of 'hay fever or nasal allergies' showed no significant difference in prevalence between the two study phases, a standardized repeatability similar to that for CRS, and an unstandardized kappa (72.8) indicating good agreement.

Association of symptoms with endoscopy and self-reported doctor-diagnosed CRS

Three hundred and forty-two participants in Ghent and Amsterdam underwent nasal endoscopy. Table 3 shows the associations of symptom-based CRS with endoscopy and self-reported doctor-diagnosed CRS, stratified for current allergic rhinitis. Overall, 61.7% (95% CI: 50.3 - 72.3%) of symptom-positive subjects had a positive endoscopy, and 38.0% (32.3 - 44.1%) of symptom-negative subjects had a positive endoscopy. Of positive endoscopies, 33.6% (26.0 - 41.7%) had CRS symptoms, and 83.9% (77.9-88.8) of negative endoscopies had no CRS symptoms. 31.4% (21.8 - 42.3) of symptom-positive and 11.1% (7.7 - 15.4%) of symptom-negative subjects had a self-reported doctor-diagnosed CRS. Symptom-based CRS was significantly associated with a positive endoscopy (OR 2.62; 95%CI [1.57 - 4.39]; $p < 0.001$) and with middle meatal purulent secretions and middle meatal oedema. The association of symptom-based CRS to a positive endoscopy was stronger in subjects without current allergic rhinitis (OR 3.78; $p<0,001$) compared to subjects with allergic rhinitis (OR 1.45; $p = 0.437$), and the Mantel-Haenszel-corrected OR was comparable with the uncorrected OR (OR 2.41 [1.43 - 4.05], $p<0,001$) (Table 3). The Breslow-Day test showed no significant differences between odds ratios of each subgroup. Symptom-based CRS was associated with a self-reported doctor-diagnosed CRS (OR 3.67 [2.03 - 6.60], $p<0.001$). This association was not modified by the presence of allergy (adjusted OR 3.62 [1.97 - 6.63], Breslow-Day $p=0,871$).

DISCUSSION

The revised EP3OS consensus document provided diagnostic criteria for CRS in 2007, and we have applied these criteria in a two phase, multi-center, questionnaire based cross-sectional epidemiological study, the GA²LEN Survey and the GA²LEN Survey Follow-Up. Endoscopic findings characteristic of CRS (as defined by the EP3OS criteria) and the reporting of doctor-diagnosed CRS was used to assess the validity of the reported symptoms for defining CRS in this setting.

1
2
3 254 We used three parameters to assess reliability of the CRS questionnaire: standardized difference in prevalence,
4
5 255 standardized absolute repeatability and unstandardized kappa statistic. When using general population surveys to
6
7 256 describe between center differences in chronic disease prevalence, a prevalence estimate that is stable over time
8
9 257 is needed, even though individual changes (disease incidence and disease remission) may be occurring within the
10
11 258 population. The absence of change in prevalence implies that, at population level, the number of subjects who
12
13 259 are asymptomatic in the first phase but have symptoms in the second phase is equivalent to the number of those
14
15 260 with symptoms in the first phase who report no symptoms in the second phase. We observed a decrease in
16
17 261 prevalence of CRS between the two occasions. We also observed a decrease in prevalence for ‘wheezing with
18
19 262 breathlessness’, a commonly used symptom question in respiratory epidemiology. The magnitude of the
20
21 263 difference for CRS was equivalent to that seen for ‘wheezing with breathlessness’ and most importantly showed
22
23 264 no variation between centers. This means that there is no evidence that the broad interpretation of geographical
24
25 265 variation in prevalence of disease using this instrument will be affected (that is, the error is constant across
26
27 266 populations).

28
29 267 Absolute repeatability was high for all questions, and to some extent this is not surprising as within subject
30
31 268 agreement for low prevalence conditions is likely to be solely due to chance. Unstandardized repeatability
32
33 269 (Cohen’s κ) was fair to moderate for CRS questions and for symptom-based CRS definition, whereas it was
34
35 270 moderate to good for asthma and nasal allergy. Cohen’s kappa is a widely accepted measure to assess chance
36
37 271 corrected agreement (11) but it has been argued that in questionnaire development for assessing symptoms in
38
39 272 population based studies (where the prevalence of the outcome is low) survey items should not be rejected on the
40
41 273 basis of kappa alone (10). Other parameters should be considered, including change in prevalence and measures
42
43 274 of validity against clinical criteria.

44
45 275 Development of instruments suitable for the epidemiological investigation of CRS is hampered by the lack of an
46
47 276 easily measurable gold standard definition of disease. We compared symptom criteria to endoscopy and to self-
48
49 277 reported doctor-diagnosed CRS, which are assumed to be highly specific, but not sensitive, for chronic
50
51 278 rhinosinusitis. We demonstrated significant associations of the symptom criteria with positive endoscopy and
52
53 279 doctor-diagnosed CRS. Of subjects who had positive symptoms, 62% had a positive endoscopy, whereas 38% of
54
55 280 symptom-negative patients had a positive endoscopy. As patients in this study were required to have chronic
56
57 281 symptoms in the last 12 months but not necessarily at the time of endoscopy, we expect that a small proportion
58
59 282 of endoscopy-negative patients may have had a positive endoscopy during active symptoms and vice versa. To
60
283 our knowledge, this study is the first to document endoscopy in asymptomatic subjects.

284 In line with work of Stankiewicz (12) investigating CT and endoscopy in CRS patients, we observe that only a
285 proportion of symptom-positive patients had a positive endoscopy. However, in that study, only 29% of
286 participants had a positive endoscopy, while 62% of our symptom-positive subjects had a positive endoscopy.
287 This difference could be explained by less strict symptom criteria, and the exclusion of nasal polyp patients and
288 patients with purulence on rhinoscopy. In a large hospital based study in Istanbul, Tahamiler (13) reports that in
289 768 patients with CRS fulfilling the EP3OS symptom criteria, 31.3% of allergic patients and 24.7% of non-
290 allergic patients had a positive nasal endoscopy. This is a much smaller proportion than in our study
291 (respectively 58% and 65%), but the reason for the difference is unclear, as this study used even less strict
292 criteria for positivity of endoscopy.

293 In the diagnosis of CRS, controversy exists whether or not to corroborate positive symptoms with endoscopy and
294 CT (14). The EP3OS criteria propose a confirmation by either CT or endoscopy. As it is not possible to include
295 CT in epidemiological studies involving healthy subjects, we can only hypothesize that some of our participants
296 with positive symptoms but negative endoscopy may have had radiographic evidence of disease. In fact, in a
297 study comparing CT and endoscopy using a proprietary scoring system in CRS patients (15), 65% of endoscopy
298 negative patients had radiographic evidence of disease. In another study (12), this proportion was 36%.
299 Extrapolating these data to our population, we can estimate that 76% to 87% of our symptom-based CRS
300 diagnoses would be confirmed by endoscopy or CT had both been available.

301 The study by Tahamiler suggests that the association of symptom-based CRS with objective markers of disease
302 is not greatly influenced by the presence of allergic rhinitis. However there is overlap in the symptoms
303 associated with each condition, particularly for nasal obstruction and rhinorrhoea (16-18). Therefore, we might
304 expect a weaker association of symptom-based CRS with objective markers of disease in subjects with allergic
305 rhinitis. We addressed this question by stratifying our analyses for current allergic rhinitis. The strength of the
306 association of a positive endoscopy with CRS symptoms was weaker in presence of allergic rhinitis, although we
307 found no statistically significant evidence for this (Breslow-Day test for interaction, $p = 0,074$). However, it has
308 been shown that the statistical power for testing interaction is too low in many epidemiological studies (19).
309 Although our observations could be explained by an overlap of CRS and allergic rhinitis symptoms, endoscopic
310 findings such as oedema can also be present in both diseases. This may account for a high proportion (49,3%) of
311 positive endoscopies in CRS-negative allergic rhinitis patients. In contrast with endoscopy, symptom-based CRS
312 was associated with self-reported doctor-diagnosed CRS, irrespective of the presence of allergic rhinitis. Taken
313 together, these findings suggest that a symptom-based definition of CRS is stable, irrespective of the presence of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

allergic rhinitis, and that positivity of the endoscopic criteria may be influenced by the presence of allergic rhinitis. Further research of the specificity of symptom criteria and endoscopy in relation to radiologic changes is warranted.

CONCLUSION

We have for the first time assessed the reliability of the symptom-based EP3OS definition for epidemiological diagnosis of chronic rhinosinusitis. Our findings suggest that a symptom-based definition of CRS has a moderate reliability over time, is stable between study centers, is not influenced by the presence of allergic rhinitis, and suitable for the epidemiological assessment of geographic variation in prevalence of CRS.

REFERENCES

1. Min YG, Jung HW, Kim HS, Park SK, Yoo KY. Prevalence and risk factors of chronic sinusitis in Korea: results of a nationwide survey. *Eur Arch Otorhinolaryngol* 1996;253(7):435-9.
2. Collins JG. Prevalence of selected chronic conditions: United States, 1990-1992. *Vital Health Stat* 10 1997(194):1-89.
3. Chen Y, Dales R, Lin M. The Epidemiology of Chronic Rhinosinusitis in Canadians. *Laryngoscope* 2003;113(7):1199-1205.
4. Shashy RG, Moore EJ, Weaver A. Prevalence of the chronic sinusitis diagnosis in Olmsted County, Minnesota. *Arch Otolaryngol Head Neck Surg* 2004;130(3):320-3.
5. Fokkens W, Lund V, Mullol J. European position paper on rhinosinusitis and nasal polyps 2007. *Rhinol Suppl* 2007(20):1-136.
6. Lund VJ, Mackay IS. Staging in rhinosinusitis. *Rhinology* 1993;31(4):183-4.
7. Mackay IS, Lund VJ. Imaging and staging. In: Mygind N, Lilholdt T, editors. *Nasal Polyposis, an Inflammatory Disease and Its Treatment*. Copenhagen: Munksgaard; 1997. p. 137-144.
8. Edwardes MD. A confidence interval for $\Pr(X < Y) - \Pr(X > Y)$ estimated from simple cluster samples. *Biometrics* 1995;51(2):571-8.
9. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21(11):1539-58.
10. Chinn S, Burney PG. On measuring repeatability of data from self-administered questionnaires. *Int J Epidemiol* 1987;16(1):121-7.
11. Fleiss JL. Measuring nominal scale agreement among many raters. *Psychological Bulletin* 1971;76(5):378-382.
12. Stankiewicz JA, Chow JM. Nasal endoscopy and the definition and diagnosis of chronic rhinosinusitis. *Otolaryngol Head Neck Surg* 2002;126(6):623-627.
13. Tahamiler R, Canakcioglu S, Ogreden S, Acioglu E. The accuracy of symptom-based definition of chronic rhinosinusitis. *Allergy* 2007;62(9):1029-1032.
14. Bhattacharyya N. Clinical and symptom criteria for the accurate diagnosis of chronic rhinosinusitis. *Laryngoscope* 2006;116(7 Pt 2 Suppl 110):1-22.
15. Casiano RR. Correlation of clinical examination with computer tomography in paranasal sinus disease. *Am J Rhinol* 1997;11(3):193-6.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

353 16. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its
354 Impact on Asthma (ARIA) 2008 Update (in collaboration with the World Health Organization, GA²LEN* and
355 AllerGen**). Allergy 2008;63(s86):8-160.

356 17. Wallace DV, Dykewicz MS, Bernstein DI, Blessing-Moore J, Cox L, Khan DA, et al. The diagnosis and
357 management of rhinitis: An updated practice parameter. J Allergy Clin Immunol 2008;122(2, Supplement 1):S1-
358 S84.

359 18. Charpin D, Sibbald B, Weeke E, Wüthrich B. Position paper*. Allergy 1996;51(5):293-298.

360 19. Marshall S. Power for tests of interaction: effect of raising the Type I error rate. Epidemiol Perspect
361 Innov 2007;4(1):4.

For Peer Review

Table 1: Instruments used in the Ga²len Survey and Survey Follow-Up: EP3OS criteria for the diagnosis of chronic rhinosinusitis, and excerpts from the questionnaire.

EP3OS criteria for diagnosis of chronic rhinosinusitis

- Presence of two or more of the following symptoms:
 - Nasal blockage, obstruction or congestion
 - Nasal discharge (either anterior or posterior nasal drip)
 - Facial pain or pressure
 - Reduction or loss of smell
 One of which should be blockage or discharge
 Symptoms should be present during > 12 weeks without complete resolution

AND EITHER:

- Endoscopic signs of
 - Polyps, and /or
 - Mucopurulent discharge, primarily from middle meatus, and/ or
 - Oedema or obstruction primarily in middle meatus
 - CT changes: mucosal changes within the ostiomeatal complex and / or sinuses
-

Survey questionnaire

For assessing CRS as per EP3OS

- Has your nose been blocked for more than 12 weeks during the last 12 months?
- Have you had pain or pressure around the forehead, nose or eyes for more than 12 weeks during the last 12 months?
- Have you had discoloured nasal discharge or discoloured mucus in the throat for more than 12 weeks during the last 12 months?
- Has your sense of smell been reduced or absent for more than 12 weeks during the last 12 months?

Additional

- Has a doctor ever told you that you have chronic sinusitis or nasal polyps?
 - Do you have any nasal allergies, including hay fever?
-

Table 2: Standardized change in prevalence between Survey and Follow-Up, standardized absolute repeatability and unstandardized kappa, for questionnaire items and for symptom-defined chronic rhinosinusitis and asthma. Between-center heterogeneity is expressed as I². SOB = shortness of breath.

Outcome	N	Standardized prevalence in survey (%)	Standardized difference in prevalence					Absolute repeatability	Kappa
			Diff. (%)	95% CI	p	Tests for heterogeneity			
						I ²	p value		
Chronic rhinosinusitis	1700	9.3	-3.0	[-5.0 to -1.0]	0.003	0.0	0.570	91.8	39.6
Blocked nose	1687	13.3	1.3	[-4.8 to 7.3]	0.680	52.5	0.026	84.7	45.4
Pain or pressure	1691	7.2	-3.1	[-5.0 to -1.2]	0.002	50.5	0.034	93.0	35.7
Discoloured nasal discharge	1687	6.8	-1.5	[-2.7 to -0.3]	0.012	45.6	0.057	93.3	33.5
Reduced sense of smell	1683	6.9	-1.0	[-1.9 to -0.1]	0.034	55.3	0.018	95.4	53.0
Doctor-diagnosed CRS	1685	2.9	5.7	[0.2 to 11.2]	0.040	52.0	0.028	92.3	48.8
Asthma	1700	8.0	1.3	[-0.1 to 2.7]	0.066	41.5	0.082	96.5	82.3
Wheezing with SOB	1602	13.3	-3.8	[-9.3 to 1.8]	0.180	58.9	0.001	89.6	54.6
Nasal allergy	1618	41.8	0.1	[-1.8 to 2.0]	0.900	8.5	0.360	92.0	72.8

Table 3: Associations of symptom-based CRS with endoscopy and self-reported doctor-diagnosed CRS, stratified for current allergic rhinitis (n = 342). Interaction effects were tested with Breslow-Day's test. AR = allergic rhinitis.

	Crude odds ratio			Subjects without current AR		Subjects with current AR		Breslow Day test	Mantel-Haenszel adjusted odds ratio		
	OR	95% CI	p (chi ²)	OR	95% CI	OR	95% CI	p	adj. OR	95% CI	p
Midde meatal findings											
Purulent secretions	3.36	[1.55 - 7.31]	0.003	4.30 [1.58 - 11.7]		2.33 [0.67 - 8.17]		0.454	3.29 [1.49 - 7.25]		0.003
Oedema	2.63	[1.58 - 4.37]	<0.001	3.67 [1.81 - 7.45]		1.46 [0.68 - 3.12]		0.080	2.36 [1.41 - 3.94]		0.001
Positive endoscopy	2.62	[1.57 - 4.38]	<0.001	3.78 [1.84 - 7.75]		1.45 [0.67 - 3.13]		0.074	2.41 [1.43 - 4.05]		0.001
Doctor-diagnosed CRS	3.66	[2.03 - 6.60]	<0.001	3.79 [1.71 - 8.43]		3.43 [1.37 - 8.60]		0.871	3.62 [1.97 - 6.63]		<0.001

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Standardized difference in prevalence between Survey and Follow-Up for each center (squares) and for the whole sample (diamonds), for CRS, asthma and allergic rhinitis.

For Peer Review

A. Chronic rhinosinusitis **B. Asthma** **C. Allergic rhinitis**

Figure 1. Standardized difference in prevalence between Survey and Follow-Up for each center (squares) and for the whole sample (diamonds), for CRS, asthma and allergic rhinitis.
87x205mm (600 x 600 DPI)